Precision diagnosis and treatment of liver cancer in China
Authors:
Top Cited Papers
- 1 January 2018
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 412, 283-288
Abstract
No abstract availableKeywords
Funding Information
- State Key project (2015ZX09J15107)
- National Natural Science Foundation of China (81522035, 81521091, 81372206, 81472768)
- Shanghai Committee of Science and Technology (15431901600, 16QA1404900)
This publication has 86 references indexed in Scilit:
- High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomyJournal of Translational Medicine, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway†Hepatology, 2010
- Surgical management of hepatocellular carcinoma: Is the jury still out?Surgical Oncology, 2009
- α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular CarcinomaGastroenterology, 2009
- Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinomaBritish Journal of Cancer, 2009
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences, 2008